Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : FTX-101
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Find Therapeutics Receives FDA IND Clearance for FTX-101 in Chronic Optic Neuropathy
Details : FTX-101, is a first-in-class remyelinating agent that aims to restore vision in people suffering from Chronic Optic Neuropathy (CON), by modulating myelin blocking complex.
Brand Name : FTX-101
Molecule Type : Peptide
Upfront Cash : Not Applicable
August 27, 2024
Lead Product(s) : FTX-101
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?